Nanotechnology in Medicine: Drug Delivery, Diagnostics, a...

Innovation & Technology · 2 · October 28, 2025

The COVID-19 mRNA vaccines (Pfizer, Moderna) were the world's introduction to nanomedicine — lipid nanoparticles delivering genetic instructions to cells. That same delivery platform is now being adapted for cancer treatment, gene therapy, and targeted drug delivery.

Nanoparticle Drug Delivery: Precision Targeting

Lipid nanoparticles (LNPs) can encapsulate drugs and deliver them to specific cell types — reducing systemic side effects while increasing drug concentration at the target. Onpattro (patisiran), the first FDA-approved siRNA therapy, uses LNPs to deliver gene-silencing molecules specifically to liver cells for hereditary transthyretin amyloidosis.

In oncology, antibody-drug conjugates (ADCs) attach chemotherapy molecules to antibodies that recognize cancer-specific surface proteins. Enhertu (trastuzumab deruxtecan) targets HER2-positive cells and has shown remarkable results in breast and lung cancer — delivering chemotherapy directly to tumor cells while minimizing damage to healthy tissue. ADC market revenue exceeded $10 billion in 2025.

Liquid Biopsy: Cancer Detection from a Blood Draw

Circulating tumor DNA (ctDNA) can be detected in a standard blood sample — no surgical biopsy needed. Guardant360 CDx and Foundation Medicine's FoundationOne Liquid CDx analyze ctDNA to identify specific cancer mutations, guide treatment selection, and monitor response. Grail's Galleri test screens for 50+ cancer types from a single blood draw — though its sensitivity for early-stage cancers remains limited (25-30% for stage I). These tests cost $900-$3,500 in the US, $200-$800 in India.

What's Next: Nanobots and Theranostics

True nanorobots — autonomous machines operating inside the body — remain experimental, but theranostics (therapy + diagnostics in one nanoparticle) is here. Lutathera — a radiolabeled peptide — simultaneously images and treats neuroendocrine tumors. The Prostate-Specific Membrane Antigen (PSMA) theranostic approach images prostate cancer with Ga-68 PSMA PET and treats it with Lu-177 PSMA radioligand therapy. These dual-purpose nanoparticles are available at advanced nuclear medicine centers in India, Germany, and Australia.

Key Takeaways

- COVID mRNA vaccines proved lipid nanoparticle drug delivery at global scale

- Antibody-drug conjugates deliver chemo directly to cancer cells — $10 billion market in 2025

- Liquid biopsy tests detect cancer DNA from a blood draw — $200-$800 in India vs $900-$3,500 in US

- Theranostics (combined diagnosis + treatment) is available for prostate and neuroendocrine cancers

Compare real-time pricing using our global cost calculator.